CAJ | 학술논문

目的：评价利妥昔单抗联合改良CHOP方案（600 mg? m－2环磷酰胺，第1天＋1．4 mg? m－2长春新碱，第1天＋泼尼松60 mg，第1～5天＋25 mg? m－2阿霉素，第1天）治疗复发难治性非霍奇金淋巴瘤的临床疗效及安全性。方法将62例复发难治性非霍奇金淋巴瘤患者随机分为试验组29例和对照组33例。对照组：改良 CHOP 方案联合10 mg? m－2博来霉素，第1天＋75 mg? m－2足叶乙苷，第1～5天；试验组：在改良CHOP方案实施前2 d，静脉输注375 mg? m－2利妥昔单抗。2组1个周期均为21 d，共治疗4～6个周期。分析比较2组患者的临床疗效及不良反应发生率。结果试验组的客观缓解率93．10％显著高于对照组75．76％（P＜0．05）。试验组平均缓解时间（14．6±3．8）个月显著长于对照组（6．4±2．2）个月（P＜0．05）。2组患者不良反应发生率比较差异无统计学意义（P＞0．05）。结论利妥昔单抗联合改良CHOP方案治疗复发难治性非霍奇金淋巴瘤临床的疗效确切，可显著延长患者的疾病缓解时间。
목적：평개리타석단항연합개량CHOP방안（600 mg? m－2배린선알，제1천＋1．4 mg? m－2장춘신감，제1천＋발니송60 mg，제1～5천＋25 mg? m－2아매소，제1천）치료복발난치성비곽기금림파류적림상료효급안전성。방법장62례복발난치성비곽기금림파류환자수궤분위시험조29례화대조조33례。대조조：개량 CHOP 방안연합10 mg? m－2박래매소，제1천＋75 mg? m－2족협을감，제1～5천；시험조：재개량CHOP방안실시전2 d，정맥수주375 mg? m－2리타석단항。2조1개주기균위21 d，공치료4～6개주기。분석비교2조환자적림상료효급불량반응발생솔。결과시험조적객관완해솔93．10％현저고우대조조75．76％（P＜0．05）。시험조평균완해시간（14．6±3．8）개월현저장우대조조（6．4±2．2）개월（P＜0．05）。2조환자불량반응발생솔비교차이무통계학의의（P＞0．05）。결론리타석단항연합개량CHOP방안치료복발난치성비곽기금림파류림상적료효학절，가현저연장환자적질병완해시간。
Objective To assess the effects and safety of rituximab com-bined with CHOP chemotherapy regimen ( 600 mg? m-2 cytoxan on day 1+1.4 mg? m-2 vinblastine on day 1+prednisone 60 mg on day 1 to 5+25 mg? m-2 adriamycin on day 1 ) in the treatment of relapsing non-hodgkin′s lymphoma.Methods A total of 62 cases of relapsing non-hodgkin′s lymphoma were divided into experiment group ( n=29 ) and control group ( n =33 ) .Patients in the control group were given CHOP regimen combined with 10 mg? m-2 bleomycin on day 1 and 5 mg? m-2 etoposide on day 1 to 3.Patients in experiment group were given 375 mg? m-2 rituximab 2 days before CHOP chemotherapy.All of the patients underwent 4 to 6 cycles of chemotherapy (21 days was a cy-cle).The clinical effects and adverse reactions were evaluated between the two groups.Results The objective response rate were 93.10%and 75.76%in experiment and control group respectively ( P <0.05 ) .The mean complete response time were ( 14.6 ±3.8 ) months in experiment group, higher than(6.4 ±2.2) months in control group( P<0.05).The main adverse reaction in two groups were not statistically different (P>0.05).Conclusion Rituximab combined with CHOP chemothera-py regimen can improve the clinical efficacy and complete response time on patients with relapsing non-hodgkin′s lymphoma.